EGFR and neoplasm: Excitingly, interim results of a Phase I clinical trial assessing intrathecal efficacy of bivalent CAR-T cells targeting EGFR and IL-13R-alpha-2 in six recurrent glioblastoma patients demonstrated improvements in tumor size and enhancement, substantial CAR T cell abundance, and significant cytokine release in the cerebrospinal fluid in all six patients (53).